<!DOCTYPE html>
<html lang="zh-CN">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=5.0">
    <title>ç§‘ç ”æ—¥æŠ¥ - 2026-01-20</title>
    <style>
        * {
            margin: 0;
            padding: 0;
            box-sizing: border-box;
        }

        body {
            font-family: -apple-system, BlinkMacSystemFont, "Segoe UI", Roboto, "Helvetica Neue", Arial, "Noto Sans", sans-serif, "Apple Color Emoji", "Segoe UI Emoji";
            line-height: 1.8;
            color: #2c3e50;
            background: linear-gradient(135deg, #f5f7fa 0%, #c3cfe2 100%);
            padding: 15px;
            font-size: 16px;
        }

        .container {
            max-width: 900px;
            margin: 0 auto;
            background: white;
            padding: 35px;
            border-radius: 16px;
            box-shadow: 0 10px 40px rgba(0,0,0,0.1);
        }

        /* æ ‡é¢˜ä¼˜åŒ– */
        h1 {
            color: #1a202c;
            font-size: 2em;
            border-bottom: 4px solid #667eea;
            padding-bottom: 15px;
            margin-bottom: 25px;
            font-weight: 700;
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            -webkit-background-clip: text;
            -webkit-text-fill-color: transparent;
            background-clip: text;
        }

        h2 {
            color: #2d3748;
            font-size: 1.5em;
            margin-top: 40px;
            margin-bottom: 20px;
            padding-left: 15px;
            border-left: 5px solid #667eea;
            font-weight: 600;
        }

        h3 {
            color: #4a5568;
            font-size: 1.25em;
            margin-top: 28px;
            margin-bottom: 14px;
            font-weight: 600;
        }

        /* åˆ†ç±»æµè§ˆæŠ˜å åŠŸèƒ½ */
        details {
            margin: 20px 0;
            border-radius: 8px;
            overflow: hidden;
        }

        details summary {
            cursor: pointer;
            padding: 15px 20px;
            background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%);
            color: #2d3748;
            font-size: 1.25em;
            font-weight: 600;
            text-align: right;
            direction: rtl;
            border-right: 5px solid #667eea;
            transition: all 0.3s ease;
            list-style: none;
            user-select: none;
        }

        details summary * {
            direction: ltr;
        }

        details summary::-webkit-details-marker {
            display: none;
        }

        details summary::before {
            content: 'â–¶';
            display: inline-block;
            margin-left: 10px;
            transition: transform 0.3s ease;
            font-size: 0.8em;
        }

        details[open] summary::before {
            transform: rotate(90deg);
        }

        details summary:hover {
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            color: white;
            box-shadow: 0 4px 12px rgba(102, 126, 234, 0.3);
        }

        details[open] summary {
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            color: white;
            border-right-color: white;
        }

        details .details-content {
            padding: 20px;
            background: white;
            border: 1px solid #e9ecef;
            border-top: none;
        }

        h4 {
            color: #718096;
            font-size: 1.1em;
            margin-top: 22px;
            margin-bottom: 12px;
            font-weight: 600;
        }

        p {
            margin-bottom: 16px;
            line-height: 1.8;
        }

        blockquote {
            background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%);
            border-left: 4px solid #667eea;
            padding: 18px 22px;
            margin: 22px 0;
            border-radius: 8px;
            color: #4a5568;
            font-size: 0.95em;
            box-shadow: 0 2px 8px rgba(0,0,0,0.05);
        }

        blockquote p {
            margin-bottom: 8px;
        }

        blockquote p:last-child {
            margin-bottom: 0;
        }

        blockquote em {
            font-style: normal;
            color: #718096;
            font-size: 0.9em;
        }

        blockquote a {
            color: #667eea;
            font-weight: 500;
            border-bottom: 1px solid rgba(102, 126, 234, 0.3);
        }

        blockquote a:hover {
            color: #764ba2;
            border-bottom-color: #764ba2;
        }

        /* é¡¶éƒ¨ç½²åï¼ˆå±…å³ï¼‰ */
        .powered-by-top {
            text-align: right;
            font-size: 0.85em;
            color: #718096;
            font-style: italic;
            margin: 12px 0;
            padding-right: 5px;
        }

        .powered-by-top a {
            color: #667eea;
            font-weight: 500;
            border-bottom: 1px solid rgba(102, 126, 234, 0.3);
        }

        .powered-by-top a:hover {
            color: #764ba2;
            border-bottom-color: #764ba2;
        }

        /* AI æ€»ç»“åŒºåŸŸä¼˜åŒ– */
        .ai-summary {
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            color: white;
            padding: 28px;
            border-radius: 16px;
            margin: 30px 0;
            box-shadow: 0 12px 35px rgba(102, 126, 234, 0.35);
            position: relative;
            overflow: hidden;
        }

        .ai-summary::before {
            content: '';
            position: absolute;
            top: -50%;
            right: -50%;
            width: 200%;
            height: 200%;
            background: radial-gradient(circle, rgba(255,255,255,0.1) 0%, transparent 70%);
            pointer-events: none;
        }

        .ai-summary h2 {
            color: white;
            border-left: none;
            border-right: none;
            margin-top: 0;
            margin-bottom: 18px;
            padding-left: 15px;
            padding-right: 0;
            text-align: left;
            direction: ltr;
        }

        .ai-summary h3 {
            color: #f0f0f0;
            margin-top: 18px;
            border-right: 3px solid rgba(255,255,255,0.5);
            padding-right: 12px;
            padding-left: 0;
            text-align: right;
            direction: rtl;
        }

        .ai-summary h3 * {
            direction: ltr;
        }

        .ai-summary blockquote {
            background: rgba(255,255,255,0.15);
            border-left-color: white;
            color: white;
            backdrop-filter: blur(10px);
        }

        .ai-summary p {
            color: white;
        }

        .ai-summary strong {
            color: #fff;
            font-weight: 600;
        }

        ul, ol {
            margin-left: 28px;
            margin-bottom: 18px;
        }

        li {
            margin-bottom: 12px;
            line-height: 1.8;
        }

        /* é“¾æ¥ä¼˜åŒ– */
        a {
            color: #667eea;
            text-decoration: none;
            border-bottom: 1px solid transparent;
            transition: all 0.3s ease;
            font-weight: 500;
        }

        a:hover {
            border-bottom-color: #667eea;
            color: #764ba2;
        }

        /* è¡¨æ ¼ä¼˜åŒ– */
        table {
            width: 100%;
            border-collapse: collapse;
            margin: 20px 0;
            box-shadow: 0 2px 12px rgba(0,0,0,0.08);
            border-radius: 10px;
            overflow: hidden;
        }

        th, td {
            border: 1px solid #e2e8f0;
            padding: 14px 18px;
            text-align: left;
        }

        th {
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            color: white;
            font-weight: 600;
            font-size: 0.95em;
        }

        tr:nth-child(even) {
            background: #f8f9fa;
        }

        tr:hover {
            background: #e9ecef;
            transition: background 0.3s ease;
        }

        /* å…³é”®è¯ç»Ÿè®¡è¡¨æ ¼ç‰¹æ®Šæ ·å¼ï¼ˆæ›´ç´§å‡‘ï¼‰ */
        .keywords-table {
            font-size: 0.9em;
            max-width: 600px;
        }

        .keywords-table th,
        .keywords-table td {
            padding: 10px 14px;
        }

        .keywords-table th {
            font-size: 0.9em;
        }

        hr {
            border: none;
            border-top: 2px solid #e2e8f0;
            margin: 40px 0;
        }

        strong {
            color: #2d3748;
            font-weight: 600;
        }

        code {
            background: #f1f5f9;
            padding: 3px 8px;
            border-radius: 5px;
            font-family: "SF Mono", Monaco, Consolas, "Courier New", monospace;
            font-size: 0.9em;
            color: #e53e3e;
        }

        /* ç¾åŒ–æ»šåŠ¨æ¡ */
        ::-webkit-scrollbar {
            width: 8px;
            height: 8px;
        }

        ::-webkit-scrollbar-track {
            background: #f1f1f1;
            border-radius: 4px;
        }

        ::-webkit-scrollbar-thumb {
            background: #667eea;
            border-radius: 4px;
        }

        ::-webkit-scrollbar-thumb:hover {
            background: #764ba2;
        }

        /* ç§»åŠ¨ç«¯ä¼˜åŒ– */
        @media (max-width: 768px) {
            body {
                padding: 8px;
                font-size: 15px;
            }

            .container {
                padding: 22px 18px;
                border-radius: 12px;
            }

            h1 {
                font-size: 1.6em;
                padding-bottom: 12px;
                margin-bottom: 20px;
            }

            h2 {
                font-size: 1.3em;
                margin-top: 30px;
                padding-left: 12px;
            }

            h3 {
                font-size: 1.15em;
            }

            h4 {
                font-size: 1.05em;
            }

            blockquote {
                padding: 14px 16px;
                margin: 18px 0;
            }

            .ai-summary {
                padding: 20px;
                margin: 22px 0;
            }

            .ai-summary-header {
                flex-direction: column;
                align-items: flex-start;
            }

            .powered-by {
                margin-left: 0;
                margin-top: 8px;
            }

            table {
                font-size: 0.85em;
            }

            th, td {
                padding: 10px 12px;
            }

            .keywords-table {
                font-size: 0.8em;
            }

            .keywords-table th,
            .keywords-table td {
                padding: 8px 10px;
            }

            ul, ol {
                margin-left: 22px;
            }
        }

        /* è¶…å°å±å¹• */
        @media (max-width: 480px) {
            body {
                font-size: 14px;
                padding: 5px;
            }

            .container {
                padding: 18px 14px;
            }

            h1 {
                font-size: 1.4em;
            }

            h2 {
                font-size: 1.2em;
            }

            .ai-summary {
                padding: 16px;
            }

            .powered-by {
                font-size: 0.7em;
            }
        }

        /* å¹³æ»‘æ»šåŠ¨ */
        html {
            scroll-behavior: smooth;
        }

        /* æé«˜å¯ç‚¹å‡»åŒºåŸŸ */
        @media (pointer: coarse) {
            a {
                padding: 4px 0;
                display: inline-block;
            }
        }

        /* æ‰“å°ä¼˜åŒ– */
        @media print {
            body {
                background: white;
                padding: 0;
            }

            .container {
                box-shadow: none;
                max-width: 100%;
            }

            .ai-summary {
                background: #f5f5f5;
                color: black;
                box-shadow: none;
            }

            .ai-summary h2,
            .ai-summary h3,
            .ai-summary p,
            .ai-summary strong {
                color: black;
            }
        }
    </style>
</head>
<body>
    <div class="container">
        <h1>ğŸ“… Daily Report - 2026-01-20</h1>
<blockquote>
<p>ä»Šæ—¥ç­›é€‰å‡º <strong>15</strong> æ¡å†…å®¹ï¼Œæ¥è‡ª <strong>2</strong> ä¸ªæ¥æº</p>
</blockquote>
<div class="powered-by-top">Powered by <a href="https://kyplus.de" target="_blank" rel="noopener noreferrer">ç§‘ç ”æ™®æ‹‰æ–¯</a> & <a href="https://claude.ai" target="_blank" rel="noopener noreferrer">Claude</a></div>

<hr />
<div class="ai-summary">
                <h2>ğŸ¤– ä»Šæ—¥AIæ™ºèƒ½æ€»ç»“</h2>
                <h3>ğŸ§¬ æ•°æ®å‰æ²¿</h3>
<blockquote>
<p><strong>ä»Šæ—¥ç„¦ç‚¹</strong>ï¼š<br />
FXR1è¢«é‰´å®šä¸ºåµå·¢ç™ŒsiRNAç–—æ³•çš„å¯é¶å‘æ²»ç–—é¶ç‚¹ï¼›åˆ©ç”¨ç”²åŸºåŒ–æ•°æ®è¿›è¡Œç»†èƒåå·ç§¯ï¼Œæ­ç¤ºäº†ä¸‰é˜´æ€§ä¹³è…ºç™Œé¢„åç›¸å…³çš„å…ç–«å­¦ç‰¹å¾ã€‚</p>
</blockquote>
<p><strong>ä¸»è¦æ–¹å‘</strong>ï¼š<br />
- ç™Œç—‡æ²»ç–—é¶ç‚¹å‘ç°ä¸æ–°ç–—æ³•æ¢ç´¢ï¼ˆå¦‚åµå·¢ç™ŒFXR1é¶å‘siRNAç–—æ³•ï¼ŒCMLè€è¯å¹²ç»†èƒçš„FBXO3ä»‹å¯¼çš„MAPKä¿¡å·é€šè·¯è°ƒæ§ï¼‰ã€‚<br />
- å…ç–«å¾®ç¯å¢ƒä¸ç–¾ç—…å‘ç”Ÿå‘å±•çš„å…³ç³»ï¼ˆå¦‚TNBCçš„å…ç–«æµ¸æ¶¦ï¼Œæœ‰ç›Šç¯å¢ƒå¯¹å…ç–«éŸ§æ€§çš„è¡¨è§‚é—ä¼ è°ƒæ§ï¼‰ã€‚<br />
- æ¤ç‰©ç”Ÿé•¿å‘è‚²çš„åˆ†å­æœºåˆ¶è§£æï¼ˆå¦‚æ°´ç¨»æŠ½ç©—æœŸåŸºå› è°ƒæ§ï¼Œé»„ç“œæ ªå‹å¡‘é€ ï¼‰ã€‚</p>
<p><strong>æŠ€æœ¯äº®ç‚¹</strong>ï¼š<br />
- ç»“åˆå¤šç»„å­¦ï¼ˆå¦‚å•ç»†èƒå››ç»„å­¦ï¼‰è§£æåŸºå› è°ƒæ§ç½‘ç»œã€‚<br />
- åŸºäºDNAç”²åŸºåŒ–æ•°æ®çš„ç»†èƒåå·ç§¯æŠ€æœ¯ã€‚</p>
<h3>ğŸ§ª åšå®¢æ›´æ–°</h3>
<blockquote>
<p><strong>ä»Šæ—¥ç„¦ç‚¹</strong>ï¼š<br />
ç§‘å­¦å®¶é¦–æ¬¡å‘ç°å…ç–«è°ƒèŠ‚é…¶OTULINæ˜¯tauè›‹ç™½åœ¨å¤§è„‘ä¸­ç§¯ç´¯çš„å…³é”®è§¦å‘å™¨ï¼Œå…¶å¤±æ´»å¯é€†è½¬å¤§è„‘è¡°è€è¿¹è±¡ã€‚</p>
</blockquote>
<p><strong>ä¸»è¦æ–¹å‘</strong>ï¼š<br />
- é¶å‘OTULINä»¥æ¸…é™¤tauè›‹ç™½ï¼Œå»¶ç¼“æˆ–é€†è½¬è„‘è¡°è€ã€‚<br />
- æ¢ç´¢OTULINåœ¨ç¥ç»å…ƒå¥åº·ä¸­çš„ä½œç”¨æœºåˆ¶ã€‚</p>
<p><strong>æŠ€æœ¯äº®ç‚¹</strong>ï¼š<br />
- é¦–æ¬¡æ­ç¤ºOTULINä¸tauè›‹ç™½ç§¯ç´¯çš„ç›´æ¥å…³è”ã€‚<br />
- é€šè¿‡åŸºå› ç¼–è¾‘æŠ€æœ¯ï¼ˆOTULINå¤±æ´»ï¼‰å®ç°tauè›‹ç™½æ¶ˆå¤±ï¼Œè„‘ç»†èƒå¥åº·ã€‚</p>
            </div><h2>ğŸ“š åˆ†ç±»æµè§ˆ</h2>
<details>
<summary style="text-align: right; direction: rtl; padding: 10px 15px; background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%); border-right: 4px solid #667eea; font-weight: 600; cursor: pointer; margin: 15px 0; border-radius: 6px;">ğŸ§¬ æ•°æ®å‰æ²¿ (14æ¡)</summary>
<div class="details-content">
<h4>è¯¦ç»†å†…å®¹ï¼ˆå‰10æ¡ï¼‰</h4>
<p><strong>1.</strong> â­ <strong>GSE292799 å•ç»†èƒè½¬å½•ç»„å­¦æ­ç¤º FXR1 æ˜¯åµå·¢ç™Œ siRNA æ²»ç–—çš„å¯æ“ä½œé¶ç‚¹</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šcancerã€single-cellã€transcriptomics<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Jasmine George ; Xiaolong Ma ; Ishaque Pulikkal Kadamberi ; Ajay Nair ; Sonam Mittal ; Elaheh Hashemi ; Sudhir Kumar ; Mona SinghSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusOvarian cancer is one of the leading causes of cancer-related mortality among women and remains exceptionally difficult to manage and treat effectively in the clinic. Fragile X-related protein 1 (FXR1) is significantly amplified and overexpressed in ovarian and various other cancers. We have shown that FXR1 acts as a key regulator of the stability and translation of multiple oncogenic mRNAs, establishing it as an excellent therapeutic target for ovarian cancer. Our Single-cell RNA sequencing (scRNA-seq) analysis demonstrates a complex involvement of FXR1 in cancer progression mainly due to its dual role attributed through its autonomous actions in tumor cells and the modulation of tumor microenvironment (TME). Recent advances in RNA interference (RNAi) therapies have enabled targeting previously undruggable genes. In this study, we developed a locked nucleic acid (LNA)-based small interfering RNA (siRNA) to target FXR1 for ovarian cancer therapy. Compared to native siRNA, siFXR1-LNA demonstrates resistance to RNase degradation, improved tumor tissue uptake, and robust inhibition of its target FXR1. siFXR1-LNA inhibited proteins essential for tumor growth and survival while increasing the levels of pro-apoptotic proteins. Importantly, the polyethylenimine-mediated delivery of siFXR1-LNA effectively reduced tumor growth and peritoneal metastasis in ovarian cancer models, without causing toxicity in both immunocompromised and immunocompetent mice. scRNA-seq further revealed that siFXR1-LNA treatment not only suppressed FXR1 in cancer cells but also disrupted translation mechanisms linked to oncogenesis. In TME, siFXR1-LNA diminished tumor cell proliferation, reduced tumor-promoting M2-like macrophages, increased tumor inhibitory T and NK cells and increased dendritic cells with anti-tumor characteristics. Given the autonomous role of FXR1 in tumor cells and TME for oncogenesis, targeting FXR1 with siFXR1-LNA presents a unique opportunity for treating ovarian cancer and other cancers express high levels of FXR1.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE292799" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>2.</strong> â­ <strong>GSE308164 åŸºäºç”²åŸºåŒ–çš„ä¸‰é˜´æ€§ä¹³è…ºç™ŒDNAç»†èƒè§£å·ç§¯æ­ç¤ºäº†é¢„åå…ç–«ç‰¹å¾</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šcancerã€immuneã€methylation<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Sarah Williams ; Ruth Pidsley ; Clare StirzakerSeries Type : Methylation profiling by genome tiling arrayOrganism : Homo sapiensIn triple negative breast cancer (TNBC), immune infiltration is now recognised as playing an important role in prognosis. DNA methylation, due to its cell-type specificity, offers a promising approach for quantifying immune cell abundance as a biomarker for risk stratification. Here, we used EpiDISH, a DNA methylation-based cellular deconvolution method, to estimate immune cell proportions from genome-wide methylation data across three independent cohorts, including TNBC patients. We show that increased immune cell percentage in TNBC patients specifically, was associated with longer disease-specific survival, highlighting the potential of DNA methylation-based estimates of cell composition for prognosis in TNBC.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE308164" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>3.</strong> â­ <strong>GSE307573 æœ‰ç›Šçš„ç¯å¢ƒé€šè¿‡è¡¨è§‚é—ä¼ è°ƒæ§ä¿ƒè¿›å…ç–«éŸ§æ€§[scRNA-seq]</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šimmuneã€scRNAã€epigenetic<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Theodoros Kapellos ; Guilherme Dragunas ; Yuexin Chen ; Herbert Schiller ; Zeynep ErtrÃ¼z ; Ali Ã–nder YildirimSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusEnvironmental factors are often detrimental; however, certain environments enhance immune resilience. Notably, children raised on traditional farms show reduced allergies and asthma prevalence. Here, we investigated how a beneficial environment, using farm dust (FD) extract, influenced lung immune function in OVA-induced allergic inflammation. FD-exposure reduced allergic lung inflammation and increased monocyte-derived macrophage (MDM) recruitment. scRNA-seq revealed that FD-exposed MDMs had altered gene expression, including dampened Ccl8 and MHCII expression, impairing eosinophil recruitment and antigen presentation. RNA-seq and ATAC-seq confirmed FD-induced epigenetic reprogramming ex-vivo, on bone marrow-derived macrophages. This modulation, seen in both human and murine cells, relied on HDAC activity sustained by PPARÎ³ signaling. These findings suggest that beneficial environmental exposures can reprogram immune cells and may offer a novel strategy for asthma prevention.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE307573" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>4.</strong> <strong>GSE287046 è‚ é“é™åˆ¶æ€§LXRæ¿€åŠ¨å‰‚çš„ç‰¹æ€§åŠå…¶åœ¨æ”¹å–„å®éªŒæ€§çŸ­è‚ ç»¼åˆå¾è‚æŸä¼¤ä¸­çš„åº”ç”¨</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šgutã€regex:gut(-?microbiome)?<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Ayoung Kim ; Lingaiah Maram ; Hannah M Phelps ; Jichang Han ; Rachel L Mintz ; Brad W Warner ; Bahaa Elgendy ; Gwendalyn J RandolphSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusShort bowel syndrome (SBS) results from the surgical removal of extensive portions of the small intestine and is associated with high morbidity, including intestinal failure-associated liver disease (IFALD). We aim to identify effective, targeted therapies to combat IFALD while promoting small intestinal remodeling that optimizes intestinal health and nutrient absorption. Following previous findings that an LXR agonist administered orally suppresses liver injury in a mouse model of SBS, we sought application of a gut-restricted LXR agonist to avoid potential for systemic activation of LXR. We synthesized and characterized WUSTL0717 as a potential gut-restricted hydrophobic derivative of the well-known LXR agonist GW3965and tested its ability to improve outcomes in a mouse model of SBS. Pharmacokinetic analysis in mice revealed overwhelming intestinal retention of WUSTL0717. The compound activated a panoply of LXR target genes, including Abca1, in the small intestine but not the liver. It also increased ileal transcript levels of Apoa1 that encodes the core protein of high-density lipoprotein (HDL) and raised HDL levels in plasma. WUSTL0717 was efficacious in protecting against IFALD. Additionally, WUSTL0717 improved nutrient absorption after small intestinal resection and promoted restoration of body weight. These data identify the LXR agonist WUSTL0717 as a gut-restricted drug that may provide therapeutic benefits for treating SBS-associated IFALD while avoiding unwanted effects of systemic LXR agonists.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE287046" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>5.</strong> <strong>GSE303006 é€šè¿‡å•ç»†èƒå››ç»„å­¦æµ‹åºè§£æåŸºå› è°ƒæ§å›¾è°±</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šsequencingã€single-cell<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Yujie Chen ; Zhiyuan LiuSeries Type : OtherOrganism : Mus musculusEnrichment libraries and Hi-C libraries were processed using identical scripts. Initially, different read types were demultiplexed based on identification sequences in the R2 read. For RNA data, we first removed reads containing no poly-A sequence following GAT5-RT primer sequence. We then aligned Read 1 to the GRCm38 reference genome using STAR. Duplicates were removed based on UMIs with UMI-tools. RNA count matrix was generated by FeatureCounts with parameters â€œ-O -M --fractionâ€. We used RNAsnpSplit for phasing of allele- specific RNA counts.For HiC data, reads were mapped to the GRCm38 reference genome with BWA-mem2 in â€œ5SPâ€ mode. Contacts and 3D genome structures were generated with Hickit software using default parameters. To remove potential contamination from RNA reads, we cleaned contacts between two exons from the same transcript, which accounted for ~0.04% of all contacts. For quality control of reconstructed 3D genome structures, five replicates were generated with random seeds, and median RMSD for each combination of 3 replicates was calculated. The first replicate in the combination with the minimum median RMSD value (if &lt; 1.5) was used for downstream analysis. 3D proximity and 3D distance maps were generated as previously described with custom codes. For accessibility reads and histone modification reads, R2 reads, which represent Tn5 insertion sites, were aligned using BWA-mem2 with default parameters. Afterward, a custom Python script was employed to remove PCR duplicates, generating single-cell signal fragment files. For haplotype phasing, fragments were first assigned to a haplotype using SNP information from the R2 read. If the haplotype could not be determined from R2, SNP information from the R1 read was then utilized. All reads were mapped to the mm10 reference genome. All these processing steps were organized and implemented using Snakemake, and are available at https://github.com/skelviper/CHARM.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE303006" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>6.</strong> <strong>GSE308681 æœ‰ç›Šçš„ç¯å¢ƒé€šè¿‡è¡¨è§‚é—ä¼ è°ƒæ§ä¿ƒè¿›å…ç–«éŸ§æ€§</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šimmuneã€epigenetic<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Markus Klotz ; Guilherme Dragunas ; Sirui Chen ; Deepesh Dhakad ; Thomas M Conlon ; Ali Ã–nder YildirimSeries Type : Genome binding/occupancy profiling by high throughput sequencingOrganism : Mus musculusEnvironmental factors are often detrimental; however, certain environments enhance immune resilience. Notably, children raised on traditional farms show reduced allergies and asthma prevalence. Here, we investigated how a beneficial environment, using farm dust (FD) extract, influenced lung immune function in OVA-induced allergic inflammation. FD-exposure reduced allergic lung inflammation and increased monocyte-derived macrophage (MDM) recruitment. scRNA-seq revealed that FD-exposed MDMs had altered gene expression, including dampened Ccl8 and MHCII expression, impairing eosinophil recruitment and antigen presentation. RNA-seq and ATAC-seq confirmed FD-induced epigenetic reprogramming ex-vivo, on bone marrow-derived macrophages. This modulation, seen in both human and murine cells, relied on HDAC activity sustained by PPARÎ³ signaling. These findings suggest that beneficial environmental exposures can reprogram immune cells and may offer a novel strategy for asthma prevention.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE308681" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>7.</strong> <strong>GSE312362 S100A7è¡¨è¾¾é™ä½ä¸çš®è‚¤è¡°è€è¿‡ç¨‹ä¸­åˆ†åŒ–ã€è‡ªå™¬å’Œè¡°è€ç›¸å…³ç¨‹åºçš„æ”¹å˜æœ‰å…³</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šaging<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Ge Peng ; Fumihiro Hattori ; Hideoki Ogawa ; Ko Okumura ; FranÃ§ois NiyonsabaSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensTo investigate the role S100A7, a skin-derived antimicrotial peptide (AMP) in skin aging, we knockdowned S100A7 in normal human keratinocytes, which induced senescence markers, impaired autophagy, and partially recapitulated aging-associated transcriptional changes. Conversely, supplementation with physiological levels of S100A7 restored autophagic flux and attenuated senescence in D-galactoseâ€“induced aging models. These findings identify S100A7 as a molecular link between epidermal differentiation, autophagy, and cellular senescence, establishing an AMPâ€“autophagy axis in skin aging.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE312362" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>8.</strong> <strong>GSE309070 FBXO3ä»‹å¯¼çš„DUSP9æ³›ç´ åŒ–é‡ç¼–ç¨‹MAPKä¿¡å·é€šè·¯ä»¥æ ¹é™¤é…ªæ°¨é…¸æ¿€é…¶æŠ‘åˆ¶å‰‚è€è¯çš„CMLå¹²ç»†èƒ</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼škinase<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Xudong Li ; Shiyu Zuo ; Yongping Song ; Zhilei Bian ; Wei LiSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensDiscovering new therapeutic targets to overcome tyrosine kinase inhibitors (TKIs) resistance and clear leukemic stem cells (LSCs) is an urgent clinical need for chronic myeloid leukemia (CML) treatment. In the present study, we report that the F-box protein 3 (FBXO3) is upregulated in CD34+ CML stem cells from patients with TKI treatment failure and is regulated by BCR-ABL. Single-cell RNA sequencing (scRNA-seq) analysis indicated that FBXO3+ HSCs from CML patients have significant LSC signatures. Genetic depletion of FBXO3 significantly increased apoptosis and decreased proliferation of both imatinib-sensitive/resistant CML cell lines and CML stem cells in vitro and in vivo, with minimal effects on normal CD34+ HSCs. Mechanistically, FBXO3 interacts with DUSP9 and mediates its ubiquitination. DUSP9 knockdown partially counteracts the elimination of CML stem cells mediated by FBXO3 depleting in vitro and in vivo. RNA-seq results indicates that FBXO3-mediated ubiquitination of DUSP9 activates MAPK signaling pathway in CML cells. Moreover, FBXO3 inhibitor alone or in combination with imatinib significantly clear CML stem cells and overcome TKI resistance in murine and human CML, with minimal effects on normal hematopoiesis. Overall, our findings uncover novel roles of FBXO3 in CML progression and provide a rationale for combining FBXO3 inhibitors with TKIs to induce durable elimination of CML-LSCs.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE309070" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>9.</strong> <strong>GSE313855 æ¯›å¶è‹•å­ç»¿è‚¥é€šè¿‡åŠŸèƒ½è¾ƒå¼±çš„GA20oxç­‰ä½åŸºå› èµ‹äºˆçš„æŠ—å€’ä¼èƒ½åŠ›ï¼Œæé«˜äº†é«˜äº§æ—¥æœ¬æ°´ç¨»å“ç§çš„äº§é‡å’Œç±½ç²’å¤–è§‚å“è´¨</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šresistance<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Hirofumi Fukuda ; Toshihiro Sakamoto ; Akari Fukuda ; Daisuke OgawaSeries Type : Expression profiling by high throughput sequencingOrganism : Oryza sativaGreen manure is widely advocated as a sustainable alternative to chemical fertilizers in crop systems, yet the mechanisms underlying its yield benefits remain unclear. Moreover, vigorous vegetative growth under green manure can elevate lodging risk, undermining yield and harvest efficiency. Here, we describe mechanisms by which hairy vetchâ€“based green manure enhances yield and evaluate the practical value of deploying functionally weak alleles of gibberellin 20-oxidase (GA20ox) in this management context. We conducted field comparisons of green manure and conventional chemical fertilization to evaluate effects on rice productivity, grain appearance quality, and canopy physiology. Green manure significantly increased grain yield and grain appearance quality in the leading Japanese cultivar â€˜Koshihikariâ€™, accompanied by higher lodging. By contrast, high-yielding cultivars homozygous for a single-copy GA20ox1 allele and/or a non-functional GA20ox2 allele maintained superior lodging resistance under green manure treatment while improving yield and grain appearance quality, indicating an effective combination of its treatment and genotypes. Physiologically, green manure increased chlorophyll index during vegetative growth and at the reproductive stage, and nitrogen (N) concentration on the whole plant. Furthermore, green manure increased flag-leaf width and tiller number; these canopy changes were associated with reduced panicle temperature at the ripening stage. Green manure treatment induced upregulation of OsNADH-GOGAT2, a known gene associated with increased N loading to grains, and more grain storage proteins, providing a positive link to improved grain appearance quality. Collectively, this study demonstrates that integrating hairy vetch with functionally weak GA20ox alleles can enhance productivity and grain appearance quality while mitigating lodging risk. This sheds light on the importance of aligning green-manure treatment with targeted allelic selection to stabilize performance across intensive-farming systems and reduce chemical fertilizer dependency.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE313855" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>10.</strong> <strong>GSE302464 AtNUDT11ä»‹å¯¼çš„dpCoA-RNA-seqå®šä¹‰äº†è¡¨è§‚è½¬å½•ç»„dpCoAåŠ å¸½RNA</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šRNA-seq<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šSeries Type : Expression profiling by high throughput sequencingOrganism : Arabidopsis thalianaThis SuperSeries is composed of the SubSeries listed below.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE302464" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<blockquote>
<p>ğŸ’¡ è¯¥æ¥æºè¿˜æœ‰ 4 æ¡å†…å®¹ï¼Œè¯¦è§ <a href="#æ›´å¤š-æ•°æ®å‰æ²¿">æ–‡æœ«</a></p>
</blockquote>
</div>
</details>

<details>
<summary style="text-align: right; direction: rtl; padding: 10px 15px; background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%); border-right: 4px solid #667eea; font-weight: 600; cursor: pointer; margin: 15px 0; border-radius: 6px;">ğŸ§ª åšå®¢æ›´æ–° (1æ¡)</summary>
<div class="details-content">
<h4>è¯¦ç»†å†…å®¹ï¼ˆå…¨éƒ¨1æ¡ï¼‰</h4>
<p><strong>1.</strong> <strong>ç§‘å­¦å®¶å‘ç°ä¸€ç§â€œä¸»è°ƒèŠ‚å™¨â€ï¼Œæˆ–å¯é€†è½¬å¤§è„‘è¡°è€</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šaging<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šResearchers have identified OTULIN, an immune-regulating enzyme, as a key trigger of tau buildup in the brain. When OTULIN was disabled, tau vanished from neurons and brain cells remained healthy. The findings challenge long-held assumptions about tauâ€™s necessity and highlight a promising new path for fighting Alzheimerâ€™s and brain aging. Scientists now believe OTULIN may act as a master switch for inflammation and age-related brain decline.<br />
- ğŸ”— <a href="https://www.sciencedaily.com/releases/2026/01/260116035348.htm" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
</div>
</details>

<h2>ğŸ“Š å…³é”®è¯ç»Ÿè®¡</h2>
<table class="keywords-table">
<thead>
<tr>
<th>å…³é”®è¯</th>
<th>å‡ºç°æ¬¡æ•°</th>
</tr>
</thead>
<tbody>
<tr>
<td>cancer</td>
<td>3</td>
</tr>
<tr>
<td>immune</td>
<td>3</td>
</tr>
<tr>
<td>RNA-seq</td>
<td>3</td>
</tr>
<tr>
<td>aging</td>
<td>2</td>
</tr>
<tr>
<td>single-cell</td>
<td>2</td>
</tr>
<tr>
<td>epigenetic</td>
<td>2</td>
</tr>
<tr>
<td>gut</td>
<td>1</td>
</tr>
<tr>
<td>regex:gut(-?microbiome)?</td>
<td>1</td>
</tr>
<tr>
<td>kinase</td>
<td>1</td>
</tr>
<tr>
<td>sequencing</td>
<td>1</td>
</tr>
<tr>
<td>transcriptomics</td>
<td>1</td>
</tr>
<tr>
<td>resistance</td>
<td>1</td>
</tr>
<tr>
<td>methylation</td>
<td>1</td>
</tr>
<tr>
<td>scRNA</td>
<td>1</td>
</tr>
<tr>
<td>ChIP-seq</td>
<td>1</td>
</tr>
</tbody>
</table>
<hr />
<h2>ğŸ“ æ›´å¤šå†…å®¹</h2>
<details>
<summary><a name="æ›´å¤š-æ•°æ®å‰æ²¿"></a>ğŸ§¬ æ•°æ®å‰æ²¿ å…¶ä»–å†…å®¹ (4æ¡)</summary>
<div class="details-content">
<ul>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE300923" target="_blank" rel="noopener noreferrer">GSE300923 TRMT6 é€šè¿‡ç¿»è¯‘è°ƒæ§å¤šæ–¹é¢å‡è½» DSS è¯±å¯¼ç»“è‚ ç‚çš„æ˜“æ„Ÿæ€§å’Œè¿›å±• [RNA-seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE294327" target="_blank" rel="noopener noreferrer">GSE294327 PLETHORA3/7 è½¬å½•å› å­å¡‘é€ é»„ç“œèŒçš„ç»“æ„ [RNA-Seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE287449" target="_blank" rel="noopener noreferrer">GSE287449 é¶å‘ç“œæ°¨é…¸åŒ–ä½¿ p53 ä¸éç»å…¸ä½ç‚¹ç»“åˆ [ChIP-seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE273414" target="_blank" rel="noopener noreferrer">GSE273414 MRTFA-SRFé©±åŠ¨çš„åŸºå› è¡¨è¾¾é€šè¿‡æ§åˆ¶ç™Œç»†èƒä¸­ç»†èƒè´¨Ca2+å’ŒK+æ°´å¹³æ¥ä¿ƒè¿›ç»†èƒåˆšæ€§</a></li>
</ul>
</div>
</details>

<hr />
<p><em>ğŸ“… æŠ¥å‘Šç”Ÿæˆæ—¶é—´ï¼š2026-01-19 21:39</em><br />
<em>ğŸ¤– ç”± GitHub Actions è‡ªåŠ¨ç”Ÿæˆ</em></p>
    </div>
</body>
</html>